Navigation Links
Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting
Date:6/1/2009

New Product Names for Recently Introduced MicroRNA-based Diagnostics Also Unveiled

SAN DIEGO, June 1 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, presented an overview of its proprietary oncology diagnostic platform yesterday at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando.

In a presentation entitled "Profiling of Receptor Tyrosine Kinases (RTK) Activation in Circulating Tumor Cells (CTCs) in Metastatic Tumors Using Proximity Mediated Microarray Immunoassay," Prometheus demonstrated that its novel microarray platform can successfully detect the activation of key cancer pathways EGFR and HER2 in CTCs isolated from blood samples of patients with high specificity and sensitivity as high as a single cell. Testing of samples from frozen breast cancer tissues demonstrated concordance between reported HER2 status based on immunohistochemistry (IHC), a commonly used biopsy-based method, and the Prometheus diagnostic platform. Further, an analysis of CTCs from metastatic breast cancer patients showed that more than 50% of patients with HER2 negative primary tumors had CTCs with activated HER2 and approximately 30% of these patients had both activated and amplified HER2 over time. A copy of the presentation can be found on the Company's website at www.prometheuslabs.com.

"As our understanding of molecular targets and cancer pathways increases, so too does our need for sophisticated diagnostics," said Henry Pan, M.D., Ph.D., Chief Scientific and Medical Officer of Prometheus. "We believe the sensitivity and specificity of our proprietary diagnostics may help oncologists to optimize the choice of a growing number of targeted therapies for breast, lung, colorectal and other cancers. In addition, we believe the ability to isolate CTCs from whole blood and fine needle aspirates will be less invasive than current methods of biopsy and enable real-time, continuous monitoring of patients post-treatment."

Prometheus is currently implementing multiple studies in a clinical setting with an initial focus on metastatic breast cancer. The Company submitted an application for New York State approval in the first quarter of 2009 and anticipates the commercial launch of its first oncology diagnostic product thereafter upon completion of selected ongoing clinical studies.

New Product Names for MicroRNA-based Diagnostics

Prometheus also unveiled new product names at ASCO for three recently introduced microRNA-based diagnostics:

  • ProOnc TumorSource Dx (sold as miRview(TM) mets outside the U.S.), a test designed to accurately identify the primary tumor site in patients with metastatic cancer;
  • ProOnc Squamous Dx (sold as miRview(TM) squamous outside the U.S.), a test to differentiate squamous from non-squamous non-small cell lung cancer; and
  • ProOnc Mesothelioma Dx (sold as miRview(TM) meso outside the U.S.), a test to differentiate mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung and pleura.

The Company acquired exclusive U.S. rights to the three tests from Rosetta Genomics in April 2009.

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical and diagnostic company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and intends to apply these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary, high-value diagnostic testing services. By integrating pharmaceutical products and diagnostic testing services, Prometheus believes it can address the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego.

ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx are trademarks of Prometheus Laboratories Inc.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Is extra-corporal liver support with prometheus safe in patients with end-stage liver disease?
2. Updated GOLD report presents new understandings in diagnosis, treatment and prevention of COPD
3. The Art Of Maternity(TM) at Destination Maternity(R) Presents A Sacred Passage Into Motherhood; the Art of Belly Masking to Belly Casting
4. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
5. VNUS Medical Technologies Presents at William Blair Small-Cap Growth Stock Conference
6. NARSAD - Worlds Leading Mental Health Research Charity - Presents 19th Annual New York Mental Health Symposium, Oct. 19th & 20th
7. Retirement Living TV Presents Sex, Drugs and Rock N Roll
8. AviaraDx Presents at 2007 BIOCOM Investor Conference
9. NARSAD - the Worlds Leading Mental Health Research Charity - Presents 2007 Prizes for Outstanding Psychiatric Research at New York Gala, October 19th
10. California Science Center Science Matters Speakers Program Presents The Science and Ethics of Fear
11. Borgata Heart & Soul Foundation Presents Third Annual Women in Wine Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... that the company will provide alerting technology to Central Illinois Health Information ... $1.7 million in federal funds as the sole sub-recipient participating with the ...
(Date:12/5/2016)... , ... December 05, 2016 , ... Dr. Barry M. ... Cosmetic Plastic Surgery, who recently participated in the 36th Annual Cutting Edge Aesthetic Symposium ... the newest techniques for getting that perfect, yet natural-looking, nose. Dr. Weintraub, who is ...
(Date:12/5/2016)... ... December 05, 2016 , ... Florida Hospital has named Robin ... Region. McGuinness brings experience in executive leadership and clinical practice, as well as ... In her new role, that officially begins December 12, 2016, she will set ...
(Date:12/5/2016)... Franklin Lakes, NJ (PRWEB) , ... December 05, ... ... the recording studio teaming up on new songs with prolific Songwriter-Producer Corey “Chorus” ... Jamie Foxx, Kelly Rowland, Ciara, Brandy…just to name a few.     https://twitter.com/coreychorus ...
(Date:12/5/2016)... ... December 05, 2016 , ... The new knee compression sleeves come ... buy neoprene knee sleeves for lifting and any sport that requires knee ... two main aspects to provide a higher quality knee sleeve performance. Firstly it is ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)...  Wellbridge Health and Gateway Health proudly announce a dynamic ... and Medicaid plan members with specific high risk needs. ... of this group of consumers, Wellbridge combines technology and population ... insight into members, daily behaviors and lifestyle. ... , , ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... 2016 Eisai Inc. announced today new analyses ... Meeting of the American Epilepsy Society (AES). ... an adjunctive therapy for the treatment of partial onset ... primary generalized tonic-clonic seizures (PGTC) in patients with epilepsy ... see Important Safety Information for FYCOMPA, including Boxed WARNING ...
Breaking Medicine Technology: